Next 10 |
2024-05-07 21:50:26 ET Cryoport, Inc. (CYRX) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – ...
2024-05-07 16:21:45 ET More on CryoPort Cryoport Tanks On Chilling Results And Bad Decisions Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript B. Riley cuts Cryoport to neutral, cites top-line growth Seeking Alpha’s Quant Rating on CryoPort ...
Cryoport Reports First Quarter 2024 Financial Results PR Newswire Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-03 13:42:49 ET More on CryoPort Cryoport Tanks On Chilling Results And Bad Decisions Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on CryoPort Historical earnings data for CryoPort Financial informa...
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 PR Newswire NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced th...
2024-03-15 11:30:03 ET UBS analyst issues BUY recommendation for CYRX on March 15, 2024 10:00AM ET. The previous analyst recommendation was Buy. CYRX was trading at $15.21 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
2024-03-14 11:56:14 ET Summary Cryoport, Inc.'s financial results for Q4 2023 fell short of expectations, with revenue declining and a significant net loss. Despite the potential for growth in the cell and gene therapy market, Cryoport's revenue growth is expected to be modest. ...
2024-03-12 20:48:03 ET Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript March 12, 2024, 05:00 PM ET Company Participants Todd Fromer - IR, KCSA Strategic Communications Jerrell Shelton - CEO Mark Sawicki - Chief Scientific Officer Robert Stefanovich - C...
2024-03-12 16:08:07 ET More on CryoPort Seeking Alpha’s Quant Rating on CryoPort Historical earnings data for CryoPort Financial information for CryoPort Read the full article on Seeking Alpha For further details see: CryoPort GAAP EPS of -...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities ...
Cryoport Reports First Quarter 2024 Financial Results PR Newswire Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...